Form 4: Carlsmed Director Reports Significant Share Acquisitions and Preferred Stock Conversions Post-IPO

Carlsmed Director Robert Mittendorff II reported the conversion of millions of preferred shares into common stock and the purchase of over 1.3 million common shares at $15, increasing his indirect beneficial ownership to over 8.3 million shares following the company's initial public offering.

Summary

• Robert Mittendorff II, a Director of CARLSMED, INC. (CARL), reported significant changes in his indirect beneficial ownership of the company's common stock.
• On July 24, 2025, 3,680,506 shares of common stock were acquired through the automatic conversion of preferred stock held by B Capital Global Growth III, L.P.
• On the same date, an additional 1,333,333 shares of common stock were purchased at a price of $15 per share by B Capital Global Growth III, L.P.
• Further conversions on July 24, 2025, resulted in the acquisition of 2,376,472 shares of common stock from preferred stock conversions held by B Capital Healthcare I, L.P.
• Another conversion on July 24, 2025, resulted in the acquisition of 931,452 shares of common stock from preferred stock conversions held by Hornet Co-Invest, L.P.
• These transactions occurred immediately prior to the closing of the Issuer's initial public offering.
• The total indirect beneficial ownership of common stock following these reported transactions is 8,321,263 shares.
• Mittendorff is a general partner of B Capital Group Management, LP, which manages B Capital Global Growth III and B Capital Healthcare I, and Hornet-Co-Invest Investors, Ltd. is the ultimate general partner of Hornet Co-Invest. He disclaims beneficial ownership except to the extent of any pecuniary interest.

Sentiment

Score: 7

Explanation: The filing reports a significant insider purchase of common stock at the IPO price, alongside the expected conversion of preferred shares. While a Form 4 is primarily factual, an insider purchase generally signals confidence in the company's future prospects, contributing to a moderately positive sentiment.

Positives

• A Director, Robert Mittendorff II, increased his indirect beneficial ownership in CARLSMED, INC. through a direct purchase of 1,333,333 common shares at $15 per share, indicating confidence in the company's valuation at the IPO price.
• The automatic conversion of preferred stock into common stock prior to the IPO simplifies the capital structure and is a standard procedure for companies going public.

Future Outlook

The filing indicates that the transactions occurred 'immediately prior to the closing of the Issuer's initial public offering,' suggesting the IPO is either imminent or has just occurred. This implies the company is transitioning to being a publicly traded entity.

Industry Context

This filing reflects a standard process for a company undergoing an Initial Public Offering (IPO), where pre-IPO preferred stock holdings are converted into common stock. The purchase of additional common shares by a director at the IPO price is a common occurrence and can signal confidence from early investors or management in the company's public market valuation.

Related Party Transactions

• The filing details that the shares are held by B Capital Global Growth III, L.P., B Capital Healthcare I, L.P., and Hornet Co-Invest, L.P.
• The Reporting Person, Robert Mittendorff II, is a general partner of B Capital Group Management, LP, which manages B Capital Global Growth III and B Capital Healthcare I.
• Hornet-Co-Invest Investors, Ltd. is the ultimate general partner of Hornet Co-Invest.
• This establishes a clear related party relationship between the reporting person and the entities holding the shares.

Stakeholder Impact

• Shareholders: The conversion of preferred stock into common stock increases the float of common shares available for trading. The insider purchase by a director may be viewed positively by existing and potential shareholders as a sign of confidence.

Key Dates

Recommendation

The filing details an insider purchase of common stock at the IPO price by a director, which is generally a positive signal of confidence. However, as a Form 4, it provides limited information about the company's overall financial health or strategic direction. While the insider's purchase is encouraging, a comprehensive investment decision would require reviewing the full IPO prospectus and subsequent financial reports. Therefore, a 'hold' recommendation is appropriate until more detailed financial and operational data becomes available post-IPO.

Keywords

Carlsmed, CARL, SEC Form 4, Insider Transaction, Beneficial Ownership, Stock Conversion, Initial Public Offering, IPO, Preferred Stock, Common Stock, Director, Robert Mittendorff, B Capital